Protara Therapeutics (NASDAQ:TARA – Get Free Report) had its target price upped by equities research analysts at Oppenheimer from $26.00 to $30.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Monday, April 8th.
Read Our Latest Report on Protara Therapeutics
Protara Therapeutics Stock Performance
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last posted its earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.13. As a group, analysts forecast that Protara Therapeutics will post -3.56 earnings per share for the current year.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
Read More
- Five stocks we like better than Protara Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Use the MarketBeat Excel Dividend Calculator
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.